HOME > TOP STORIES

TOP STORIES

REGULATORY DPO Floats Premium Expansion, Relaxed Criteria towards FY2026 Reform

August 7, 2025
REGULATORY Chuikyo Rules Out Long-Term Care Costs in Leqembi CEA, Confirms Price Cut

August 7, 2025
REGULATORY Wegovy, Leqvio, Phozevel to Face CEA-Linked Price Cuts in November

August 7, 2025
REGULATORY MHLW Device Review Chief Pledges Evidence-Based Approvals amid Diversifying Technologies

August 6, 2025
REGULATORY MHLW Trial Office Head Vows to Make Japan a Preferred Site for Clinical Studies

August 5, 2025
REGULATORY Wage-Based Price Premiums on Drugs Not an Option, Says MHLW Insurance Chief

August 4, 2025
BUSINESS Nihon Chouzai to Go Private through Tender Offer Backed by Advantage Partners

August 1, 2025
ORGANIZATION Japan Society Poised to Set Out Criteria to Standardize Regional Formularies, Eyes August Release

July 31, 2025
REGULATORY MHLW to Link GS1 and YJ Codes in Public Database, Launch Planned for FY2028

July 30, 2025
BUSINESS Gene Therapy Deaths Spur Strategic Rethink among Biotechs, Merck Exec Notes Investor Caution

July 30, 2025
REGULATORY Post-Marketing Oversight and Regulatory Reviews Must Work as One, Says New MHLW Safety Chief

July 29, 2025
REGULATORY Astellas Employee Did Not Appeal, Prison Sentence Finalized in China

July 29, 2025
COMMENTARY Pharmaceutical Policy at a Crossroad amid Political Upheaval in Japan

July 28, 2025
REGULATORY MSD’s 21-Valent Pneumococcal Shot Nears Japan Approval; Male Use of Silgard 9 Cleared

July 25, 2025
BUSINESS Chugai to Defer Domestic Supply of Elevidys amid Safety Review

July 25, 2025
REGULATORY Santen’s Glaucoma Drug, Taisho’s Insomnia Med Up for Panel Review on July 31

July 25, 2025
REGULATORY MHLW Plans to Ease Clinical Trial Ad Rules, Eyes Notification by March-End

July 24, 2025
BUSINESS Towa Launches Task Force to Tackle Nitrosamine Impurities, Share Solutions with Peers

July 24, 2025
REGULATORY New MHLW Drug Review Chief Aims to Dispel “Barrier” Perception, Pledges Active Engagement with Industry

July 23, 2025
REGULATORY Healthcare Stakeholders Weigh Fallout after Ruling Bloc’s Election Setback

July 23, 2025

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

MHLW Floats Deducting Private-Practice Use for Re-Pricing, but Off-Cycle Cuts Possible; GLP-1 Eyed?

Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…

COMMENTARY

FY2026 Reform Debate for Drug Pricing Nears the Finish Line, Balance Needed

By Takashi Ebisawa

Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…

COLUMN

AI in HR: Navigating the Ethical Minefield

By Philip Carrigan

Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…